Detail for CD133high/CD44high cells

Full Name

CD133-high/CD44-high cells

Gene Name

Related Disease

  • Prostate Cancer [ref.1]
  • Colon Cancer [ref.2]

Therapy Method


It has been shown for many cancer types that the tumorigenic cells expressing common CSC markers, in particular CD133 and CD44, are exceptionally resistant to conventional anti-cancer drugs (such as 5-FU, oxaliplatin, irinotecan, docetaxel and others). Moreover, the number of such cells can be significantly propagated after therapy [6-13], which usually manifests as more drug-resistant and more aggressive recurrent and metastatic disease.
The taxoid SB-T-1214 possesses significant activity against colon cancer spheroids induced by and enriched with drug resistant tumorigenic CD133high/CD44high cells and efficiently inhibited expression of the majority of stem cell-related genes. While, combination with CMC2.24 increases its CSC-targeted cytotoxic and stem cell-modulating activities

Related Pathway/CSCs feature

  • Self-renewal


  • [1] Prostate cancer stem cell-targeted efficacy of a new-generation taxoid, SBT-1214 and novel polyenolic zinc-binding curcuminoid, CMC2.24.
    Botchkina, G. I., et al. (2013). PLoS One 8(9): e69884.. [ 24086245 ]
  • [2] New-generation taxoid SB-T-1214 inhibits stem cell-related gene expression in 3D cancer spheroids induced by purified colon tumor-initiating cells.
    Botchkina, G. I., et al. (2010). Mol Cancer 9: 192.. [ 20630067 ]

Back to top